Evidence map›Paper›PMID 31351471›Full record

ArticleBMC musculoskeletal disorders2019

Conditional deletion of E11/podoplanin in bone protects against load-induced osteoarthritis.

Katherine A Staines, Ekele Ikpegbu, Anna E Törnqvist, Scott Dillon, Behzad Javaheri, Anish K Amin, Dylan N Clements, David J Buttle, Andrew A Pitsillides, Colin Farquharson

Open access · goldAbstract read
In one paragraph

Article in BMC musculoskeletal disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Ablation ofJBMR plus · 2021
    Article
  8. Osteocyte Apoptosis Contributes to Cold Exposure-induced Bone Loss.Frontiers in bioengineering and biotechnology · 2021
    Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 3 countries.

Katherine A StainesSchool of Applied Sciences, Edinburgh Napier University, Sighthill Campus, Edinburgh, UK.
Ekele IkpegbuMichael Okpara University of Agriculture, Umudike, Abia State, Nigeria.
Anna E TörnqvistRheumatology and Bone Diseases Unit, Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Scott DillonRoslin Institute and R(D)SVS, The University of Edinburgh, Easter Bush, Midlothian, UK.
Behzad JavaheriComparative Biomedical Sciences, Royal Veterinary College, Royal College Street, London, UK.
Anish K AminDepartment of Orthopaedic and Trauma Surgery, Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK.
Dylan N ClementsRoslin Institute and R(D)SVS, The University of Edinburgh, Easter Bush, Midlothian, UK.
David J ButtleDepartment of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
Andrew A PitsillidesComparative Biomedical Sciences, Royal Veterinary College, Royal College Street, London, UK.
Colin FarquharsonRoslin Institute and R(D)SVS, The University of Edinburgh, Easter Bush, Midlothian, UK. colin.farquharson@roslin.ed.ac.uk.
Roslin Institute · GBRoyal Veterinary College · GBEdinburgh Napier University · GBMichael Okpara University of Agriculture · NGMRC Institute of Genetics and Molecular Medicine · GBNHS Lothian · GBUniversity of Sheffield · GB

Funding

Arthritis Research UK 20413Arthritis Research UK 20581Biotechnology and Biological Sciences Research Council BB/P013732/1Versus Arthritis 20413Versus Arthritis 20581Vetenskapsrådet 2013-455
6 · The paper itself

Abstract

backgroundSubchondral bone (SCB) thickening is one of the earliest detectable changes in osteoarthritic joints and is considered a potential trigger for subsequent articular cartilage degeneration. In this manuscript, we examine whether disruption to the SCB osteocyte network contributes to the initiation and pathogenesis of osteoarthritis.

methodsWe examined expression patterns of the glycoprotein E11/podoplanin by immunohistochemical labelling in murine, human and canine osteoarthritis models. We also examined the effects of twice-weekly administration of Bortezomib, a proteasome inhibitor which stabilises osteocyte E11 levels, to C57/BL6 wild-type male mice (1 mg/kg/day) for 8 weeks after surgical destabilisation of the medial meniscus. By inducing osteoarthritis-like changes in the right knee joint of 12-week-old male E11 hypomorphic mice (and corresponding controls) using a post-traumatic joint loading model, we also investigated whether a bone-specific E11 deletion in mice increases joint vulnerability to osteoarthritis. Articular cartilage degradation and osteophyte formation were assessed by histology and in line with the OARSI grading system.

resultsOur studies reveal increased E11 expression in osteocytes of human and canine osteoarthritic SCB. We found that Bortezomib administration had no effect on surgically-induced osteoarthritis, potentially due to a lack of the expected stabilisation of E11 in the SCB. We also found, in concordance with our previous work, wild-type mice exhibited significant load-induced articular cartilage lesions on the lateral femoral condyle (p < 0.01) and osteophyte formation. In contrast, E11 hypomorphic mice did not develop osteophytes or any corresponding articular lesions.

conclusionsOverall, these data suggest that an intact osteocyte network in the SCB contributes to the development of mechanically-driven osteoarthritis. Further, the data presented here indicate that the molecular pathways that preserve the osteocyte network, such as those driven by E11, may be targeted to limit osteoarthritis pathogenesis.

Indexed as

AnimalsBortezomibCartilage, ArticularDisease Models, AnimalDogsHumansMaleMembrane GlycoproteinsMenisci, TibialMiceMice, KnockoutOsteoarthritisOsteocytesOsteophytePodoplaninWeight-BearingBortezomibMembrane GlycoproteinsPDPN protein, humanPdpn protein, mousePodoplaninE11/podoplaninOsteoarthritisOsteocytesSubchondral bone

Identifiers

PMID31351471
PMCPMC6661085
OpenAlexW2964678463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.